Kirsten Achilles Poon

Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability

Kirsten Achilles Poon, Kelly M. Flagella, Joseph C. Beyer et al. · Toxicology and Applied Pharmacology · 2013 · 189 citations · Full text

Breast Oncology, Immunology, Cytotoxic Component +18

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

J.F. Liu, Kathleen N. Moore, Michael J. Birrer et al. · Annals of Oncology · 2016 · 132 citations · Full text

Pancreatic Cancer, Medicine, Pharmacology +6

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma

Andrew G. Polson, Marna Williams, Aimee Gray et al. · Leukemia · 2010 · 88 citations

Lymphoid Neoplasia, Medicine, Antibody-drug Conjugate +8

DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

Dongwei Li, Kirsten Achilles Poon, Shang‐Fan Yu et al. · Molecular Cancer Therapeutics · 2013 · 83 citations

Immunology, Immunotherapeutics, Immunotherapy +17

Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers

Thomas H. Pillow, Melissa M. Schutten, Shang‐Fan Yu et al. · Molecular Cancer Therapeutics · 2017 · 69 citations